Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Acupath First Commercial Lab to Offer URO17™, Innovative New Bladder Cancer Biomarker

Please log in for more information

 

Read the full article now

Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

Company Information

Acupath is a provider of sub-specialized anatomic pathology services focused on the following specialties; Urology, Gastroenterology, Dermatology, Women’s Health, Otolaryngology, Podiatry, and Hematology / Oncology. Acupath offers an extensive test menu on both a global and TC/PC basis, processes well over 150,000 specimens annually, and is one of the leading providers of cutting edge FISH testing for the detection of bladder cancer (UroVysion™), prostate cancer (PTEN ERG), breast cancer (PathVysion™), melanoma, and esophageal cancer (Barrett’s esophagus FISH). The company will launch PCR tests in late 2019, with the initial focus on Urology (urinary tract infections) and Podiatry (nail and wound).

Related Application Notes

Alissa Clinical Informatics Platform Compendium 2nd Edition

| Contributed by Agilent

Delivering precision health: the role of molecular diagnostics

| Contributed by GE

NGS technology: Trends and clinical applications

| Contributed by GE

Newsletter

Send me the latest from The Pathologist.

Sign up now

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register